Skip to main content
iBio, Inc. logo

iBio, Inc. — Investor Relations & Filings

Ticker · IBIO ISIN · US4510332038 LEI · 529900EW4RXUITGKUT34 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2026-04-29 Capital/Financing Update
Country US United States of America
Listing US IBIO

About iBio, Inc.

https://ibioinc.com/

iBio, Inc. is a preclinical-stage biotechnology company that utilizes a proprietary, AI-driven drug discovery platform to develop novel antibody therapeutics. The company focuses on creating next-generation medicines for obesity and cardiometabolic disorders, aiming to enhance metabolic health. Its technology stack integrates artificial intelligence, machine learning, and advanced computational biology to accelerate the discovery and optimization of biopharmaceuticals for difficult-to-drug targets. The company's internal pipeline consists of therapeutic candidates developed using this platform.

Recent filings

Filing Released Lang Actions
424B3 - iBio, Inc. (0001420720) (Filer)
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement No. 1' and is filed pursuant to Rule 424(b)(3), which is a SEC rule related to prospectus supplements for securities offerings. The content updates information about selling stockholders and share transfers related to a resale offering of common stock. It is a supplement to a previously filed prospectus and does not contain financial statements or detailed financial analysis. The document is focused on capital raising and share resale information, which aligns with capital/financing updates. It is not an annual report, earnings release, or any other report type. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4885 characters, which is sufficient to contain substantive information, not just a brief announcement, supporting the CAP classification with high confidence.
2026-04-29 English
8-K - iBio, Inc. (0001420720) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or disclosures by a company. The text includes announcements about clinical trial notifications and ethics approvals, as well as details about warrant expirations related to a previous offering. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is primarily an event disclosure and regulatory update. It is not a report publication announcement since it contains substantive event information rather than just announcing the availability of a report. The Form 8-K is a regulatory filing used to inform investors of material events. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-08 English
4 - iBio, Inc. (0001420720) (Issuer)
Director's Dealing
2026-03-23 English
4 - iBio, Inc. (0001420720) (Issuer)
Director's Dealing
2026-03-23 English
8-K - IBIO, INC. (0001420720) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by iBio, Inc. dated February 27, 2026. It details the entry into a material definitive agreement, specifically an Open Market Sale Agreement (ATM Agreement) with Jefferies LLC for an at-the-market offering of common stock. It also reports the termination of a prior ATM agreement. The content focuses on financing activities related to the sale of shares and the terms of the ATM agreement. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is not a report publication announcement but a current report on a capital raising transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-02-27 English
S-3 - IBIO, INC. (0001420720) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus describing the types of securities to be offered (common stock, preferred stock, debt securities, warrants, units) and explains the shelf registration process allowing multiple offerings up to a total amount. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. It is not an announcement of a report but the actual registration statement itself. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration information, confirming it is not a brief announcement or certification. Confidence is high due to clear identification of the form and content.
2026-02-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.